Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2 -amplified early stage breast cancer: a single-group, open-label, phase 2 study

Stephen E Jones; Rufus Collea; Devchand Paul; Scot Sedlacek; Anne M Favret; Ira Gore; Deborah L Lindquist; Frankie Ann Holmes; Mary Ann K Allison; Barry D Brooks; Raul M Portillo; Svetislava J Vukelja; Michael S Steinberg; Christopher Stokoe; Maria W Crockett; Yunfei Wang; Lina Asmar; Nicholas J Robert; Joyce O'Shaughnessy

doi:10.1016/s1470-2045(13)70384-x

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2 -amplified early stage breast cancer: a single-group, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(13)70384-x ◽

2013 ◽

Vol 14 (11) ◽

pp. 1121-1128 ◽

Cited By ~ 76

Author(s):

Stephen E Jones ◽

Rufus Collea ◽

Devchand Paul ◽

Scot Sedlacek ◽

Anne M Favret ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Phase 2 ◽

Single Group ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase

Get full-text (via PubEx)

Faculty of 1000 evaluation for Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718100767.793485107 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Phase 2 ◽

Single Group ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase

Get full-text (via PubEx)

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-11-0288 ◽

2011 ◽

Vol 17 (21) ◽

pp. 6905-6913 ◽

Cited By ~ 126

Author(s):

Richard S. Finn ◽

Carmelo Bengala ◽

Nuhad Ibrahim ◽

Henri Roché ◽

Joseph Sparano ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Single Agent ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase

Get full-text (via PubEx)

A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer

Investigational New Drugs ◽

10.1007/s10637-013-9973-4 ◽

2013 ◽

Vol 31 (5) ◽

pp. 1300-1306 ◽

Cited By ~ 18

Author(s):

K. H. Park ◽

J. H. Sohn ◽

S. Lee ◽

J. H. Park ◽

S. Y. Kang ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Open Label ◽

Tac Chemotherapy ◽

Open Label Phase

Get full-text (via PubEx)

Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple‐negative , early‐stage breast cancer ( NeoCART ): Results from a multicenter, randomized controlled, open‐label phase II trial

International Journal of Cancer ◽

10.1002/ijc.33830 ◽

2021 ◽

Author(s):

Liulu Zhang ◽

Zhi‐Yong Wu ◽

Jie Li ◽

Ying Lin ◽

Zhenzhen Liu ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Open Label ◽

Randomized Controlled ◽

Open Label Phase

Get full-text (via PubEx)

NEOTALA: an open-label, single-arm, multi-center, phase 2 study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple negative breast cancer (TNBC)

The Breast ◽

10.1016/s0960-9776(19)30271-1 ◽

2019 ◽

Vol 44 ◽

pp. S73-S74

Author(s):

J. Litton ◽

F. Symmans ◽

K. Gogineni ◽

M. Saltzman ◽

M.L. Telli ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Early Stage ◽

Neoadjuvant Treatment ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study

Get full-text (via PubEx)

A Phase 2 Study of Hypofractionated Partial Breast Irradiation (HF-PBI) in Women with Early Stage Breast Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2018.07.1611 ◽

2018 ◽

Vol 102 (3) ◽

pp. e584-e585

Author(s):

P. Fang ◽

E. Bloom ◽

W.A. Woodward ◽

M.C. Stauder ◽

W. Tereffe ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Partial Breast Irradiation ◽

Phase 2 ◽

Breast Irradiation ◽

Phase 2 Study

Get full-text (via PubEx)

Abstract P1-12-05: Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage breast cancer

10.1158/1538-7445.sabcs15-p1-12-05 ◽

2016 ◽

Author(s):

K Cadoo ◽

PA Kaufman ◽

C Hudis ◽

C Chang ◽

E Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Adjuvant Treatment ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Phase 2 ◽

Eribulin Mesylate ◽

Phase 2 Study ◽

Dose Dense

Get full-text (via PubEx)

Abstract P6-20-07: Efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial findings from a multicenter, open-label phase 2 study

10.1158/1538-7445.sabcs18-p6-20-07 ◽

2019 ◽

Author(s):

G Vidal ◽

K Kalinsky ◽

E Stringer-Reasor ◽

F Lynce ◽

J Cole ◽

...

Keyword(s):

Breast Cancer ◽

Small Molecule ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Molecule Inhibitor ◽

Phase 2 Study ◽

Open Label Phase

Get full-text (via PubEx)

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00163-7 ◽

2016 ◽

Vol 17 (6) ◽

pp. 791-800 ◽

Cited By ~ 259

Author(s):

Luca Gianni ◽

Tadeusz Pienkowski ◽

Young-Hyuck Im ◽

Ling-Ming Tseng ◽

Mei-Ching Liu ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Randomised Trial ◽

Locally Advanced ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Her2 Positive Breast Cancer ◽

Open Label Phase ◽

Positive Breast Cancer

Get full-text (via PubEx)

Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1005 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1005-1005 ◽

Cited By ~ 1

Author(s):

Guy Heinrich Maria Jerusalem ◽

Elena Kovalenko ◽

Denise A. Yardley ◽

Richard H. De Boer ◽

Sara A. Hurvitz ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor Receptor ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Open Label Phase ◽

Epidermal Growth

Get full-text (via PubEx)